I.1 How to conduct clinical trials in elderly cancer patients: clinical issues

2006 ◽  
Vol 60 ◽  
pp. S1
Author(s):  
J.-P. Droz ◽  
C. Terret
Keyword(s):  
Clinical Trials ◽  
Cancer Patients ◽  
Clinical Issues ◽  
Elderly Cancer Patients

Clinical experiences of gene therapy.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e17561-e17561
Author(s):  
Longjiang Li
Keyword(s):  
Gene Therapy ◽  
Clinical Trials ◽  
Cancer Patients ◽  
Treatment Protocol ◽  
Modern Medicine ◽  
Therapeutic Effects ◽  
Clinical Experiences ◽  
Clinical Issues ◽  
Dosage Calculation ◽  
Promising Treatment

e17561 Background: Based on the theoretic and clinical development of modern medicine, gene therapy has been a promising treatment strategy for cancer and other patients. Methods: In the present paper, we reviewed the history and clinical experiences of gene therapy from the aspects of treatment protocol, administration cycle, dosage calculation and evaluation of therapeutic effects, in order to provide more information for the further development of this promising treatment. Results: Although the development of gene therapy has not gone smoothly since the beginning of the clinical trials, the results showed that this was a promising treatment for the cancer patients. There are still a lot of researches needed to be done to further solve the theoretic and clinical issues, and to improve the therapeutic effects. Conclusions: : In conclusion, although the development of gene therapy has not gone smoothly since the beginning of the clinical trials, the results showed that this was a promising treatment for the cancer patients. There are still a lot of researches needed to be done to further solve the theoretic and clinical issues, and to improve the therapeutic effects. But the future of the gene therapy will be bright, and it will become a new basic strategy to help more patients.

Status of geriatric oncology in India: A national multicentric survey of oncology professionals

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 16035-16035
Author(s):  
B. Arora ◽  
P. M. Parikh ◽  
R. Nair ◽  
A. Vora ◽  
S. Gupta ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Elderly Patients ◽  
Cancer Patients ◽  
Clinical Care ◽  
Performance Status ◽  
Geriatric Oncology ◽  
Standard Of Care ◽  
Poor Performance Status ◽  
Elderly Cancer Patients ◽  
Medical Oncologists

16035 Background: Elderly cancer patients are underrepresented in cancer services utilization and clinical research in India. National data on providers’ knowledge, attitude and practices with regard to elderly cancer patients is sparse and is urgently required to address needs of this vulnerable and growing population. Methods: A self administered questionnaire was mailed to nationally representative sample of practicing oncologists all over India. 112 Oncologists (Medical Oncologists-51%; Radiation Oncologists-25%; Surgical Oncologists-20%; allied fields-4%) responded out of 250 mailed Questionnaires. Results: A designated Geriatric Oncology unit is in existence in very few (<5%) centers. Majority (51%) considered patients with chronological age of >60 years as elderly for India. Although 75% of elderly patients receive some therapy, only 50% of potentially curable patients and a similar percentage of potentially incurable patients receive standard of care. Also, 50% patients require modification in their treatment and only two-third of treated patients complete therapy. The existent barriers to treatment included poor performance status (53%), advanced stage (16%), and co-morbidities (15%). Only 51% Oncologists always discussed and 28% always enrolled elderly patients in clinical trials. Standard of care and evidence based recommendations for elderly patients were felt to be lacking by 49% and 92% of respondents respectively. The need of separate trials for elderly and a separate discipline of Geriatric Oncology was voiced by 93% and 89% of respondents respectively. Major differences in treatment practice between medical oncologists and non medical oncologists are shown in table . Conclusions: Treatment practices and accrual of elderly cancer patients in clinical trials in India is far from optimal. Formation of a National Geriatric Oncology society and creation of designated Geriatric oncology services at key centers may enhance the understanding and clinical care of this population. [Table: see text] No significant financial relationships to disclose.

Global history and clinical experiences of gene therapy: A brief review.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e17562-e17562
Author(s):  
Yi Li
Keyword(s):  
Gene Therapy ◽  
Clinical Trials ◽  
Cancer Patients ◽  
Treatment Protocol ◽  
Modern Medicine ◽  
Therapeutic Effects ◽  
Clinical Experiences ◽  
Clinical Issues ◽  
Dosage Calculation ◽  
Promising Treatment

e17562 Background: Based on the theoretic and clinical development of modern medicine, gene therapy has been a promising treatment strategy for cancer and other patients. Methods: In the present paper, we reviewed the history and clinical experiences of gene therapy from the aspects of treatment protocol, administration cycle, dosage calculation and evaluation of therapeutic effects, in order to provide more information for the further development of this promising treatment. Results: although the development of gene therapy has not gone smoothly since the beginning of the clinical trials, the results showed that this was a promising treatment for the cancer patients. There are still a lot of researches needed to be done to further solve the theoretic and clinical issues, and to improve the therapeutic effects. Conclusions: In conclusion, although the development of gene therapy has not gone smoothly since the beginning of the clinical trials, the results showed that this was a promising treatment for the cancer patients. There are still a lot of researches needed to be done to further solve the theoretic and clinical issues, and to improve the therapeutic effects. But the future of the gene therapy will be bright, and it will become a new basic strategy to help more patients.

scholarly journals Comprehensive Approach for Clinical Trials in Elderly Cancer Patients in an Aging Society of Korea

2014 ◽  
Vol 25 ◽  
pp. v7
Author(s):  
Hyun Cheol Chung ◽  
Sang Joon Shin ◽  
Sun Young Rha ◽  
Joong Bae Ahn ◽  
Hei Cheul Jeung
Keyword(s):  
Clinical Trials ◽  
Cancer Patients ◽  
Comprehensive Approach ◽  
Elderly Cancer Patients ◽  
Aging Society

Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center study.

1994 ◽  
Vol 12 (11) ◽  
pp. 2447-2452 ◽  
Author(s):  
S Giovanazzi-Bannon ◽  
A Rademaker ◽  
G Lai ◽  
A B Benson
Keyword(s):  
Clinical Trials ◽  
Elderly Patients ◽  
Cancer Patients ◽  
Phase Ii ◽  
Performance Status ◽  
Cancer Center ◽  
Phase Ii Trials ◽  
Elderly Cancer Patients ◽  
Treatment Interruptions ◽  
Treatment Tolerance

PURPOSE Past research that has compared cancer treatment tolerance between elderly and nonelderly cancer patients has been contradictory. Some investigators concluded that there is no difference between the groups, while others demonstrated elderly patients experienced less tolerance to treatment. As a result, some physicians discriminate against elderly cancer patients by not entering them onto clinical trials out of a belief that they will not tolerate the therapy. METHODS An analysis was performed using the Illinois Cancer Center (ICC) data base, which contains treatment information for all patients registered onto phase II trials. A maximum of 672 cases was available for evaluation of 11 treatment-related variables. RESULTS The results demonstrated no significant differences between elderly and nonelderly patients for the following seven treatment-related variables: performance status (PS), number of dose reductions, number of treatment interruptions, total days of delay, best response, reason off-study, and number of grade 3 or greater toxicities. Minor differences were detected for number of courses and number of dose escalations. CONCLUSION Based on these results, elderly patients should not be denied access to cancer clinical trials relative to age alone.

scholarly journals Changes in the use of end points in clinical trials for elderly cancer patients over time

2017 ◽  
Vol 28 (10) ◽  
pp. 2606-2611 ◽  
Author(s):  
O. Le Saux ◽  
C. Falandry ◽  
H.K. Gan ◽  
B. You ◽  
G. Freyer ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Cancer Patients ◽  
End Points ◽  
Elderly Cancer Patients ◽  
Over Time

scholarly journals Recent advances in de-intensification of radiotherapy in elderly cancer patients

F1000Research ◽  
2020 ◽  
Vol 9 ◽  
pp. 447
Author(s):  
Isacco Desideri ◽  
Viola Salvestrini ◽  
Lorenzo Livi
Keyword(s):  
Prostate Cancer ◽  
Lung Cancer ◽  
Clinical Trials ◽  
Cancer Patients ◽  
Older Patients ◽  
The Elderly ◽  
Phase Iii ◽  
Elderly Cancer Patients ◽  
Individualized Care ◽  
Whole Breast Radiotherapy

Cancer in the elderly remains an evolving issue and a health challenge. Several improvements in the radiotherapy field allow the delivery of higher doses/fractions with a safe toxicity profile, permitting the reduction of radiation treatment protocols in the elderly. Regarding breast, prostate, and lung cancer, the under-representation of older patients in clinical trials limits the extension of treatment recommendations to elderly patients in routine clinical practice. Among the feasible alternatives to standard whole breast radiotherapy (WBRT) in older patients are shorter courses using higher hypofractionation (HF) and accelerated partial breast irradiation (APBI). The boost continues to be used in women at high risk of local recurrence but is less widely accepted for women at lower risk and patients over 70 years of age. Regarding prostate cancer, there are no published studies with a focus on the elderly. Current management decisions are based on life expectancy and geriatric assessment. Regimens of HF and ultra-HF protocols are feasible strategies for older patients. Several prospective non-randomized studies have documented the safe delivery of ultra-HF for patients with localized prostate cancer, and multiple phase III trials and meta-analyses have confirmed that the HF regimen should be offered with similar acute toxicity regardless of patient age and comorbidity. A recent pooled analysis from two randomized trials comparing surgery to stereotactic body radiation therapy (SBRT) in older adult patients with early stage non-small cell lung cancer did show comparable outcomes between surgery and SBRT. Elderly cancer patients are significantly under-represented in all clinical trials. Thus, the inclusion of older patients in clinical studies should be strongly encouraged to strengthen the evidence base for this age group. We suggest that the creation of oncogeriatric coordination units may promote individualized care protocols, avoid overtreatment with aggressive and unrecommended therapies, and support de-escalating treatment in elderly cancer patients.

Sign in / Sign up

Export Citation Format

Share Document